Literature DB >> 24286642

microRNAs in breast cancer development and treatment.

Danila Serpico1, Leonardo Molino2, Serena Di Cosimo3.   

Abstract

microRNAs (herein after miRNAs) represent a recently uncovered class of small and endogenous non-coding RNAs. miRNAs play a well conserved and crucial role in normal biological processes, such as cell differentiation, proliferation and apoptosis through a complicated gene regulation networking. The recent rise of interest in miRNAs in cancer research is ascribed to the breakthrough of their role in many pathological processes, including malignant transformation. miRNAs signatures have been clearly defined for certain types of cancer, with correlation to tumor aggressiveness, therapy response and patient outcome. Furthermore, the use of miRNAs as therapeutic targets for cancer is currently under investigation. The aim of this review is to focus on the role of miRNAs in breast cancer development and to summarize the evidence for their potential diagnostic and therapeutic applications in clinical practice.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Biomarkers; Breast cancer; Targeted therapy; microRNAs

Mesh:

Substances:

Year:  2013        PMID: 24286642     DOI: 10.1016/j.ctrv.2013.11.002

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN: 0305-7372            Impact factor:   12.111


  58 in total

Review 1.  Recent trends in microRNA research into breast cancer with particular focus on the associations between microRNAs and intrinsic subtypes.

Authors:  Sasagu Kurozumi; Yuri Yamaguchi; Masafumi Kurosumi; Miki Ohira; Hiroshi Matsumoto; Jun Horiguchi
Journal:  J Hum Genet       Date:  2016-07-21       Impact factor: 3.172

2.  MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer.

Authors:  Lei Huo; Yan Wang; Yun Gong; Savitri Krishnamurthy; Jing Wang; Lixia Diao; Chang-Gong Liu; Xiuping Liu; Feng Lin; William F Symmans; Wei Wei; Xinna Zhang; Li Sun; Ricardo H Alvarez; Naoto T Ueno; Tamer M Fouad; Kenichi Harano; Bisrat G Debeb; Yun Wu; James Reuben; Massimo Cristofanilli; Zhuang Zuo
Journal:  Mod Pathol       Date:  2016-02-26       Impact factor: 7.842

3.  Potential value of circulatory microRNA122 gene expression as a prognostic and metastatic prediction marker for breast cancer.

Authors:  Amany A Saleh; Shimaa E Soliman; Mona Salah El-Din Habib; Suzy F Gohar; Ghada S Abo-Zeid
Journal:  Mol Biol Rep       Date:  2019-03-05       Impact factor: 2.316

Review 4.  Epithelial-mesenchymal transition transcription factors and miRNAs: "Plastic surgeons" of breast cancer.

Authors:  Caroline Moyret-Lalle; Emmanuelle Ruiz; Alain Puisieux
Journal:  World J Clin Oncol       Date:  2014-08-10

5.  The E3 ubiquitin ligase CHIP/miR-92b/PTEN regulatory network contributes to tumorigenesis of glioblastoma.

Authors:  Tao Xu; Hongxiang Wang; Mei Jiang; Yong Yan; Weiqing Li; Hanchong Xu; Qilin Huang; Yicheng Lu; Juxiang Chen
Journal:  Am J Cancer Res       Date:  2017-02-01       Impact factor: 6.166

6.  MicroRNA-375 targets PAX6 and inhibits the viability, migration and invasion of human breast cancer MCF-7 cells.

Authors:  Qiongyan Zou; Wenjun Yi; Jianghai Huang; Fenfen Fu; Gannong Chen; Dewu Zhong
Journal:  Exp Ther Med       Date:  2017-06-13       Impact factor: 2.447

7.  MicroRNA-132 suppresses cell proliferation in human breast cancer by directly targeting FOXA1.

Authors:  Dan Wang; Jin Ren; Hui Ren; Jin-Ling Fu; Dan Yu
Journal:  Acta Pharmacol Sin       Date:  2017-08-17       Impact factor: 6.150

Review 8.  Metformin may function as anti-cancer agent via targeting cancer stem cells: the potential biological significance of tumor-associated miRNAs in breast and pancreatic cancers.

Authors:  Bin Bao; Asfar S Azmi; Shadan Ali; Feras Zaiem; Fazlul H Sarkar
Journal:  Ann Transl Med       Date:  2014-06

Review 9.  Emergence of Circulating MicroRNAs in Breast Cancer as Diagnostic and Therapeutic Efficacy Biomarkers.

Authors:  Vaishali Aggarwal; Kumari Priyanka; Hardeep Singh Tuli
Journal:  Mol Diagn Ther       Date:  2020-04       Impact factor: 4.074

10.  MicroRNA-378-mediated suppression of Runx1 alleviates the aggressive phenotype of triple-negative MDA-MB-231 human breast cancer cells.

Authors:  Gillian Browne; Julie A Dragon; Deli Hong; Terri L Messier; Jonathan A R Gordon; Nicholas H Farina; Joseph R Boyd; Jennifer J VanOudenhove; Andrew W Perez; Sayyed K Zaidi; Janet L Stein; Gary S Stein; Jane B Lian
Journal:  Tumour Biol       Date:  2016-01-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.